Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2020). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5K12-CA138464
Bristol-Myers Squibb
Celgene
Spectrum Pharmaceuticals
Janssen Pharmaceuticals
Takeda Pharmaceuticals U.S.A.
University of California, Davis
National Cancer Institute
Sanofi
AbbVie
FWCI
0.46
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals